Literature DB >> 7790769

Lipopolysaccharide-inactivating activity of neutrophils is due to lactoferrin.

D Wang1, K M Pabst, Y Aida, M J Pabst.   

Abstract

Neutrophils can inactivate lipopolysaccharide (LPS), thereby blocking the ability of LPS to prime fresh neutrophils for enhanced fMLP-triggered release of superoxide. Here we show that inactivation of LPS by neutrophils was primarily due to lactoferrin. A time course for inactivating LPS showed that neutrophils (5 million/ml) took 30 min to inactivate 10 ng/ml LPS. Mononuclear cells could not inactivate LPS under the same conditions. Experiments with radioactive LPS showed that inactivated LPS remained in the medium and was not taken up or destroyed by the neutrophils during inactivation. Inactivated LPS still gelled Limulus lysate and primed monocytes. Cell-free medium from neutrophil suspensions also inactivated LPS. A single LPS-inactivating factor was purified from medium by heparin-agarose chromatography. SDS-PAGE showed a single band at 80 kDa, which was identified as lactoferrin by immunoblotting. Antilactoferrin immunoglobulin G removed the LPS-inactivating activity from purified lactoferrin and cell-free medium. Surprisingly, even purified neutrophil lactoferrin required 30 min to inactivate LPS, indicating inherently slow binding of lactoferrin to LPS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7790769     DOI: 10.1002/jlb.57.6.865

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  18 in total

Review 1.  Structure and biological actions of lactoferrin.

Authors:  J H Nuijens; P H van Berkel; F L Schanbacher
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-07       Impact factor: 2.673

2.  Lactoferrin protects gut mucosal integrity during endotoxemia induced by lipopolysaccharide in mice.

Authors:  M L Kruzel; Y Harari; C Y Chen; G A Castro
Journal:  Inflammation       Date:  2000-02       Impact factor: 4.092

3.  Lactoferrin-lipid A-lipopolysaccharide interaction: inhibition by anti-human lactoferrin monoclonal antibody AGM 10.14.

Authors:  D Caccavo; A Afeltra; S Pece; G Giuliani; M Freudenberg; C Galanos; E Jirillo
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

4.  The protective effects of lactoferrin feeding against endotoxin lethal shock in germfree piglets.

Authors:  W J Lee; J L Farmer; M Hilty; Y B Kim
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

5.  Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein.

Authors:  E Elass-Rochard; D Legrand; V Salmon; A Roseanu; M Trif; P S Tobias; J Mazurier; G Spik
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

6.  N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA.

Authors:  P H van Berkel; M E Geerts; H A van Veen; M Mericskay; H A de Boer; J H Nuijens
Journal:  Biochem J       Date:  1997-11-15       Impact factor: 3.857

7.  Lactoferrin regulates the activity of heparin proteoglycan-bound mast cell chymase: characterization of the binding of heparin to lactoferrin.

Authors:  G Pejler
Journal:  Biochem J       Date:  1996-12-15       Impact factor: 3.857

Review 8.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

9.  Effect of a novel tetrapeptide derivative in a model of isoproterenol induced myocardial necrosis.

Authors:  C V Ramesh; P Malarvannan; R Jayakumar; S Jayasundar; R Puvanakrishnan
Journal:  Mol Cell Biochem       Date:  1998-10       Impact factor: 3.396

10.  Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide.

Authors:  E Elass-Rochard; A Roseanu; D Legrand; M Trif; V Salmon; C Motas; J Montreuil; G Spik
Journal:  Biochem J       Date:  1995-12-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.